Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, which is in pre-clinical stage for the treatment of Japanese encephalitis virus; EV71+CA16 bivalent vaccine, which is in research stage for the treatment of hand-foot-mouth disease caused by Coxsackie A virus and enterovirus 71; and Anti-RBD monoclonal antibody, a murine monoclonal antibody for the recognition of receptor binding domain of the SARS-CoV-2 spike protein. The company was founded in 2014 and is based in Taipei, Taiwan. Enimmune Corporation is a subsidiary of Adimmune Corporation.
Frequently asked questions
What sector does Enimmune corporation (6564) operate in?
Enimmune corporation belongs to the Other sector and operates in the Biotechnology industry.
What is Enimmune corporation (6564) current stock price?
As of the latest data, Enimmune corporation stock price is NT$16.40, with a previous close of NT$16.40.
What is Enimmune corporation (6564) current market capitalization?
Enimmune corporation market cap is approximately 1.18 billion.
What is Enimmune corporation (6564) Earnings Per Share (EPS)?
The trailing EPS is -NT$2.28.
Does Enimmune corporation (6564) pay dividends?
No. Enimmune corporation does not pay a dividend.
What is Enimmune corporation (6564) beta (volatility) score?
Enimmune corporation has a beta of 0.295, indicating lower volatility than the overall market.
